ATH

33.3%

0.4¢ alterity therapeutics limited

What to hopefully look forward too, page-11

First 11 Last

Share
Profile

Follow
Scottsmyname

1,083 Posts.

103

18/08/24

18:07

Post #: 75258356
Share

Originally posted by pivalde: ↑

In the interim results, 43 % and 29 % did not sound great in investors' minds (?), so we are at a lower price level than before these results. Only 3 of 7 improved in their subjective rating scale and only 2 of 7 were stabilized according to the physician's examination. However, Stamler and Claassen were happy with these numbers. The normal worsening of these scores had been stopped in some treated patients.

According to the 434 animal study, motoric improvement became significant ( p < 0.05) only after 6 months of treatment ( Heras-Garvin et al 2021). At that time some animals had not responded yet as well as most of them—the process of how 434 works is long and complex. First iron content needs to be reduced, and then alpha-synuclein partly eliminated before any regeneration of nerves can happen. Regeneration itself is complex and needs growth factors produced, etc. This takes time even in small animals. This is a reason the length of the 201 study was increased to 1y from 7 months.

So, it looks that in 6 months there is some regeneration of motoric nerves demonstrated by improved subjective and objective ratings. But IMO improvement may well continue after 6 months. I would not be surprised after 12 months to get 43% to improve to 60% and 29% to 50%. At this level, ATH434 would be a valid treatment in those patients with symptoms for over 4 years ( a deadly disease). Let us wait to see if these numbers will improve when we get a few more 1 y results. Unfortunately when 3 cases at 6 months are missing these numbers 43% and 29 % may even get lower unless 2 of them improve.

6-month results are only an early sign of a possible positive effect by 434. That is what we have now, and even that only partially. However, 12-month results are needed, as was eventually decided by ATH.

Expand

But we wont get them results until the end of the 202 results correct ?

ATH Price at posting: 0.3¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

The market's shrugged at China's stimulus measures all year. Why is this one different?

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The winners & losers on market if negative gearing were gone

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

There are more pages in this discussion • 29 more messages in this thread...

First 11 Last

Add ATH (ASX) to my watchlist

(20min delay)
Last 0.4¢		Change 0.001(33.3%)		Mkt cap ! $21.28M

Open	High	Low	Value	Volume
0.3¢	0.4¢	0.3¢	$570	149.1K

Buyers (Bids)

No.	Vol.	Price($)
12	13513113	0.3¢

Sellers (Offers)

Price($)	Vol.	No.
0.4¢	130775819	29

View Market Depth

No.	Vol.	Price($)
12	13513113	0.003
60	77068533	0.002
27	130710099	0.001
0	0	0.000
0	0	0.000

Price($)	Vol.	No.
0.004	130775819	29
0.005	14549455	19
0.006	22531950	19
0.007	53073650	24
0.008	44655463	33

Last trade - 15.46pm 27/09/2024 (20 minute delay)

ATH (ASX) Chart

What to hopefully look forward too, page-11

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

The market's shrugged at China's stimulus measures all year. Why is this one different?

KalGold rolls out detailed aeromagnetic survey across Pinjin project

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The winners & losers on market if negative gearing were gone

ACCC seeks Olam divestments before it can buy Namoi Cotton

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

What to hopefully look forward too, page-11

Top Stories

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

The market's shrugged at China's stimulus measures all year. Why is this one different?

KalGold rolls out detailed aeromagnetic survey across Pinjin project

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The winners & losers on market if negative gearing were gone

ACCC seeks Olam divestments before it can buy Namoi Cotton

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News